Navigation Links
Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
Date:9/11/2009

GREENSBORO, N.C., Sept. 11 /PRNewswire/ -- Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

Belotero(R) Balance is a hyaluronic acid based monophasic gel dermal filler that utilizes a cohesive polydensified matrix (CPM(TM)) technology. This application seeks FDA approval for injection into mid-to-deep dermis for correction of moderate to severe wrinkles and folds.

"The FDA's acceptance for review of the Belotero(R) Balance PMA begins the application review process and signifies the beginning of Merz Pharmaceutical's firm footprint in the American aesthetics market," said Jack Britts, president and CEO of Merz Pharmaceuticals, LLC.

"Upon approval, Belotero(R) Balance will be an exciting addition to the dermal filler category," said Dr. Rhoda S. Narins, M.D., the lead investigator for the Belotero(R) clinical trials.

About Belotero(R)

First launched in Germany in 2005, Belotero(R) is also approved for aesthetic use in the United Kingdom, Italy, Russia, Austria and Switzerland.

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.


'/>"/>
SOURCE Merz Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
2. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
3. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
4. Reportlinker Adds US and European Radiopharmaceuticals Market Report
5. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
6. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
7. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
8. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
11. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner of ... and Contributor to a weeklong series of classes, meetings, field trips and special events ... Schindler and SAIL Capital have received an increasing number of awards ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an Indianapolis-based digital healthcare ... on its secure clinical communication platform. The platform allows clinicians to easily escalate ... type and urgency of a situation. , “We know from our daily ...
(Date:5/23/2017)... ... ... Therachat , a smart guided journaling tool for improving mental health, ... of anxiety in support of National Mental Health Awareness Month. , The nationwide survey ... general anxiety levels as well as identified the top triggers, impact to regular activities ...
(Date:5/22/2017)... ... , ... Today, Our Urgent Care celebrates the grand opening of its newest ... Since opening over a month ago, Our Urgent Care Washington has enjoyed serving ... Our Urgent Care walk-in clinic is located at 3195 Phoenix Center Dr., Washington, MO ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... on Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor ... excellent health education, all on their mobile phones. It also provides social networks ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... May 5, 2017  May is Stroke Awareness Month ... the most important methods to prevent a stroke: monitor ... for Disease Control and Prevention, undetected and uncontrolled hypertension ... Omron, the global leader in personal heart health technology, ... of heart attack and stroke and is advancing a ...
(Date:5/4/2017)... Mass. and SAN DIEGO ... Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and Scientific ... single-use, self-contained, illuminating medical devices, today announced the launch ... of its OfficeSPEC and ER-SPEC ... the addition of extra-small and extra-large sizes makes OBP ...
Breaking Medicine Technology: